Valuation: China Isotope & Radiation Corporation

Market Cap 3.59B 4.21B 536M 472M 447M 404M 762M 51.4B 772M 5.36B 2.06B 26.28B 2.01B 1.97B 84.44B P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 3.71B 4.35B 554M 488M 462M 417M 787M 53.1B 798M 5.53B 2.13B 27.15B 2.08B 2.03B 87.23B EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
Sep. 22 China Isotope & Radiation Unit's Lu-177 API Filing Clears US FDA Review MT
Aug. 28 China Isotope & Radiation Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Aug. 28 China Isotope & Radiation Corporation Proposes Interim Dividend for the Six Months Ended 30 June 2026, Payable on 18 December 2026 CI
Aug. 28 China Isotope & Radiation Corporation Announces Resignation of Zhang Junqi as an Executive Director, A Member of the Strategy Committee of the Board and A Member of the Science and Technology Innovation Committee of the Board, Effective August 28, 2026 CI
Aug. 28 China Isotope & Radiation Corporation Announces CEO Changes, Effective August 28, 2026 CI
Jul. 05 China Isotope to Form JV With Associate MT
Jul. 03 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
Jun. 18 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
Jun. 18 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
May. 26 China Isotope Proposes Auditor Change MT
May. 26 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
Mar. 27 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
Mar. 27 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
1 day-1.05%
1 week-6.74%
Current month-20.99%
1 month-22.71%
3 months-24.61%
6 months-37.73%
Current year-34.95%
1 week 13.02
Extreme 13.02
14.43
1 month 13.02
Extreme 13.02
17.49
Current year 13.02
Extreme 13.02
24.28
1 year 13.02
Extreme 13.02
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
26.5
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Corporate Secretary - 2024-08-29
Corporate Secretary - 2024-08-29
Comptroller/Controller/Auditor 52 2015-12-17
Director TitleAgeSince
Director/Board Member 57 2017-02-21
Director/Board Member 54 2019-06-27
Director/Board Member 54 2019-12-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-6.74%-17.88%+8.06% 541M
-2.10%-4.69%-25.75%+2.04% 175B
-0.92%-4.94%-8.17%+10.12% 111B
-0.90%+0.11%-25.55%+0.78% 107B
+0.69%+0.76%-47.04%-11.84% 75.31B
-2.39%-4.51%-2.54%+66.83% 58.7B
-1.63%-2.19%-2.72%-30.76% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-2.11%+0.13%-17.19%+19.42% 42.02B
-0.40%-3.62%+29.84%-7.51% 32.69B
Average -0.60%-1.20%-10.10%+11.10% 70.11B
Weighted average by Cap. -0.27%-1.14%-15.60%+8.99%

Financials

2024 2025
Net sales 7.57B 8.87B 1.13B 996M 943M 851M 1.61B 108B 1.63B 11.29B 4.34B 55.41B 4.25B 4.15B 178B 7.19B 8.42B 1.07B 945M 895M 807M 1.52B 103B 1.54B 10.72B 4.12B 52.58B 4.03B 3.94B 169B
Net income 407M 476M 60.71M 53.47M 50.62M 45.68M 86.24M 5.82B 87.41M 606M 233M 2.97B 228M 223M 9.56B 327M 383M 48.88M 43.06M 40.76M 36.78M 69.44M 4.68B 70.38M 488M 188M 2.4B 184M 180M 7.69B
Net Debt -109M -128M -16.26M -14.32M -13.56M -12.24M -23.1M -1.56B -23.41M -162M -62.46M -797M -61.06M -59.72M -2.56B 119M 139M 17.74M 15.63M 14.79M 13.35M 25.2M 1.7B 25.54M 177M 68.15M 869M 66.61M 65.15M 2.79B
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,655
Date Price Change Volume
26-09-30 HK$13.14 -1.05% 86,200
26-09-29 HK$13.28 -1.92% 54,600
26-09-28 HK$13.54 -0.44% 64,600
26-09-25 HK$13.60 -3.82% 100,000
26-09-24 HK$14.14 +1.00% 53,800

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock